文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

COVID-19大流行期间重症监护药物采购变化:全球时间序列研究

Changes in Purchases for Intensive Care Medicines During the COVID-19 Pandemic: A Global Time Series Study.
PubMed 文献 · Chest · 2021-08-11
一句话结论全球ICU药物采购在2020年3月激增23.6%,4-8月下降10.3%,二线药物变化最大,发展中国家绝对采购率仍低。

本研究利用覆盖全球约60%人口的药品销售数据集,分析69种ICU药物每千人采购单位数在COVID-19大流行前后的变化。干预性ARIMA模型显示,2020年3月全球ICU药物采购较2019年增加23.6%(95%CI 7.9%-37.9%,P<.001),4-8月下降10.3%(95%CI -16.9%至-3.5%,P=.006)。二线药物变化最大,发展中国家3月增加29.3%,但绝对采购率仍低;4-8月下降仅发达国家显著(-13.1%,95%CI -17.4%至-4.4%,P<.001)。采购变化与预期需求和卫生基础设施无关,提示可能存在过度采购,需政策确保未来大流行中药品公平采购。

要点

  • 2020年3月全球ICU药物采购较2019年增加23.6%(95%CI 7.9%-37.9%),4-8月下降10.3%(95%CI -16.9%至-3.5%)。
  • 二线药物采购变化最大,发展中国家2020年3月增加29.3%,但绝对采购率仍低。
  • 4-8月采购下降仅发达国家显著(-13.1%,95%CI -17.4%至-4.4%),发展中国家无显著下降。
  • 采购变化与国家层面预期需求和卫生基础设施无关,提示可能存在过度采购。
  • 全球药物采购差异持续存在,需国家和国际政策确保未来大流行中公平采购。

适用人群与场景

  • 全球药品销售数据集覆盖约60%世界人口,分析69种ICU药物采购,未提及具体纳入排除人群。

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 原文未提及

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 横断面时间序列研究,使用全球药品销售数据集(约60%世界人口),分析69种ICU药物每千人采购单位数。
  • 干预性ARIMA模型显示,2020年3月全球ICU药物采购较2019年增加23.6%(95%CI 7.9%-37.9%,P<.001)。
  • 2020年4-8月全球ICU药物采购下降10.3%(95%CI -16.9%至-3.5%,P=.006)。
  • 二线药物采购变化最大,发展中国家2020年3月增加29.3%。
  • 4-8月采购下降仅发达国家显著(-13.1%,95%CI -17.4%至-4.4%,P<.001),发展中国家绝对采购率仍低。
  • 采购变化与国家层面预期需求和卫生基础设施无关。

证据类型、等级与局限

  • 研究类型:横断面时间序列研究;证据等级未提及;局限:原文未明确提及,但设计为观察性研究,使用药品销售数据,可能受数据覆盖和混杂因素影响。

对床旁实践的改变

  • 提示未来大流行应对中需关注二线ICU药物采购激增及可能过度采购,尤其发达国家4-8月采购下降可能反映过度采购。
  • 发展中国家ICU药物绝对采购率低,需政策确保公平采购;采购变化与预期需求无关,提示采购决策可能未基于需求评估。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: Drug supply disruptions have increased during the COVID-19 pandemic, especially for medicines used in the ICU. Despite reported shortages in wealthy countries, global analyses of ICU drug purchasing during COVID-19 are limited.

RESEARCH QUESTION: Has COVID-19 impacted global drug purchases of first-, second-, and third-choice agents used in intensive care?

STUDY DESIGN AND METHODS: We conducted a cross-sectional time series study in a global pharmacy sales dataset comprising approximately 60% of the world's population. We analyzed pandemic-related changes in units purchased per 1,000 population for 69 ICU agents. Interventional autoregressive integrated moving average models tested for significant changes when the pandemic was declared (March 2020) and during its first stage from April through August 2020, globally and by development status.

RESULTS: Relative to 2019, ICU drug purchases increased by 23.6% (95% CI, 7.9%-37.9%) in March 2020 (P < .001) and then decreased by 10.3% (95% CI, -16.9% to -3.5%) from April through August (P = .006). Purchases for second-choice medicines changed the most, especially in developing countries (eg, 29.3% increase in March 2020). Despite similar relative changes (P = .88), absolute purchasing rates in developing nations remained low. The observed decrease from April through August 2020 was significant only in developed countries (-13.1%; 95% CI, -17.4% to -4.4%; P < .001). Country-level variation seemed unrelated to expected demand and health care infrastructure.

INTERPRETATION: Purchases for intensive care medicines increased globally in the month of the COVID-19 pandemic declaration, but before peak infection rates. These changes were most pronounced for second-choice agents, suggesting that inexpensive, generic medicines may be purchased more easily in anticipation of pandemic-related ICU surges. Nevertheless, disparities in access persisted. Trends seemed unrelated to expected demand, and decreased purchasing from April through August 2020 may suggest overbuying. National and international policies are needed to ensure equitable drug purchasing during future pandemics.

来源:Chest,查看原文。版权归原作者所有。

参考来源

  1. Callaway Kim K, Tadrous M, Kane-Gill SL, et al. Changes in Purchases for Intensive Care Medicines During the COVID-19 Pandemic: A Global Time Series Study. Chest. 2021. PMID: 34389295. doi:10.1016/j.chest.2021.08.007

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。